EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Congenital pulmonary airway malformation: molecular mechanisms and exploration of candidate therapeutic pathways

Ruitong Chang, Yongming Ma, Baowei Meng, Xiaogang Yang, Zhiqiang Wu, Zijiang Zhu

Frontiers in Pharmacology · 03.11.2026 · 17

DOI: 10.3389/fphar.2026.1970157 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.11.2026. Verfasst von Ruitong Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Central Hospital), Lanzhou, China. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital pulmonary airway malformation (CPAM), formerly termed congenital cystic adenomatoid malformation, is a heterogeneous developmental lung disorder characterized by abnormal cystic or adenomatous structures. Its pathogenesis remains incompletely understood and may involve disturbed lung branching morphogenesis, altered epithelial differentiation, imbalanced cell proliferation and apoptosis, focal somatic mutations, and abnormal epithelial–mesenchymal interactions. This comprehensive narrative review discusses molecular findings relevant to CPAM, including Hoxb-5, SOX2, NKX2.1/TTF-1, FGF10, WNT/BMP, EGFR, RAS–MAPK, PI3K–AKT–mTOR, ACSL5/WNT2B, FABP7, and TGF-β signaling. We distinguish evidence obtained directly from human CPAM tissue—including expression studies and somatic mutation analyses—from findings extrapolated from normal lung development, animal models, and other pulmonary disorders. Recent morphological, immunohistochemical, molecular, and single-cell studies support substantial histological and molecular heterogeneity, while the relationship between specific histological subtypes and precise developmental windows remains provisional. Chromosomal microarray analysis and sequencing may help identify selected genomic abnormalities, but most candidate pathways have not yet been validated as causal or clinically actionable targets. We summarize key evidence gaps and outline priorities for tissue-resolved profiling, functional validation in organoid and developmental models, and cautious assessment of therapeutic feasibility and safety. This review aims to provide a critical framework for interpreting current CPAM molecular evidence and guiding future translational research.

Schlagwörter

Stichwörter der Autor:innen

congenital pulmonary airway malformationscongenital pulmonary cystic adenomatoid malformationmolecular mechanismspotential targetsregulatory mechanism

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Central Hospital), Lanzhou, China.

Zitieren

APA

Chang, R., Ma, Y., Meng, B., Yang, X., Wu, Z., & Zhu, Z. (2026). Congenital pulmonary airway malformation: molecular mechanisms and exploration of candidate therapeutic pathways. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1970157

Vancouver

Chang R, Ma Y, Meng B, Yang X, Wu Z, Zhu Z. Congenital pulmonary airway malformation: molecular mechanisms and exploration of candidate therapeutic pathways. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1970157

BibTeX
@article{Chang2026,
  author = {Chang, Ruitong and Ma, Yongming and Meng, Baowei and Yang, Xiaogang and Wu, Zhiqiang and Zhu, Zijiang},
  title = {Congenital pulmonary airway malformation: molecular mechanisms and exploration of candidate therapeutic pathways},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1970157}
}
Kostenlos starten →